Apatinib/rivoceranib is a predominantly VEGFR-2-specific inhibitor which was evaluated in combination with anti-PD-1 antibody camrelizumab against sorafenib in a phase III randomized, open label trial (CARES-310), in patients with unresectable HCC, with 272 receiving the combination while 271 receiving sorafenib [164]. Here, PDCD1 is linked to hepatocellular carcinoma.